to the device costs were $5,024 per LY, $10,202 per QALY, and $11,838 per avoided CRC. Model results were most sensitive to the ADR improvement with EC over SC. Conclusions Augmenting colonoscopies with Endocuff ® in this model was shown to improve survival and quality of life, and reduce interval CRC incidence and death. In the US, it is likely to reduce lifetime costs per patient for the health plan/ACO and be cost-effective to the device purchaser. Su1014 DESPITE SHORTER LENGTH OF HOSPITAL STAYS, HOSPITALIZATION CHARGES AMONG ULCERATIVE COLITIS PATIENTS OF HISPANIC ETHNICITY ARE SIGNIFICANTLY HIGHER THAN NON-HISPANIC WHITES: AN ANALYSIS OF THE 2007-2013 NATIONWIDE INPATIENT SAMPLE Mona Rezapour, Artin Galoosian, Benny Liu, Taft Bhuket, Robert J. Wong Background and Aims: Ulcerative Colitis (UC) is a chronic disease with significant disease burden and high resource utilization. As hospitalizations among UC patients contributes to the burden on the healthcare system, we aim to evaluate disparities in length of stay (LOS) and hospitalization charges among U.S. adults with UC. Methods: Using data from the 2007- 2013 Nationwide Inpatient Sample, the largest publicly available inpatient healthcare database in the U.S., U.S. adults hospitalized with a primary diagnosis of UC were evaluated to determine total hospital LOS and total hospitalization charges stratified by age, sex, race/ ethnicity, and insurance status. Multivariate linear regression models were utilized to evaluate for predictors of UC hospitalization LOS and total hospitalization charges. Results: Among 49,871 UC hospitalizations, mean hospital LOS decreased from 6.3 days in 2007 to 5.7 days in 2013, whereas mean hospitalization charges increased from $31,449 in 2007 to $43,128 in 2013. When stratified by age, UC hospitalizations among patients age <20 years and age > 60 years had the longest mean LOS (6.83 days and 6.78 days respectively, p<0.01) and the highest mean hospitalization charges ($41,902 and $42,485 respectively, p<0.01) compared to those ages 20-59 years. When stratified by race/ethnicity, African American and Hispanic UC patients have the shortest mean hospital LOS with Hispanic patients also having the highest hospitalization charges. However, African American UC patients have the lowest hospitalization charges. When stratified by insurance, Medicare patients have disproportionately longer mean hospital LOS (6.8 days) and higher hospitalization charges ($42,450) as compared to patients with Medicaid or commercial insurance. On multivariate linear regression models, compared to patients age < 20 years, UC hospitalizations among patients age 20-39 years had significantly shorter LOS (coefficient -1.27, 95% CI -1.53 - -1.00, p<0.01). Compared to non-Hispanic whites, African Americans (coefficient -0.32 days, 95% CI 0.52- -0.12, p<0.002) and Hispanics (coefficient -0.38 days, 95% CI 0.59- -0.17, p<0.01) had shorter LOS with Hispanics also having significantly higher hospitalization charges (coefficient $5178, 95% CI 2,694-7,661, p<0.01). Interestingly, African American had significantly lower hospitalization charges (coefficient -$5,346.38, 95% CI -6,918- -3,775, p<0.01). Compared to commercially insured patients, UC patients with Medicare had longer LOS (coefficient 0.52 days, 95% CI 0.28-0.75, p<0.01) and higher hospitalization charges (coefficient $2,714, 95% CI 363-5,064, p<0.03). Conclusion: Among U.S. adults hospitalized for a primary diagnosis of UC, Hispanics and African Americans had shorter hospital LOS, but Hispanics had significantly higher hospitalization charges compared to non-Hispanic whites. Su1015 COST-UTILITY OF SCREENING FOR RENAL DYSFUNCTION TO DETECT THE ONSET AND PROGRESSION OF CHRONIC KIDNEY DISEASE AMONG ELDERLY PATIENTS TREATED WITH PROTON-PUMP INHIBITORS Jeff Y. Yang, Emily H. Chang, Stephanie Wheeler, Evan S. Dellon BACKGROUND: Proton-pump inhibitors (PPIs) have been associated with chronic kidney disease (CKD), which is a concern given the high prevalence of PPI use in the U.S. While screening for renal dysfunction has been shown to be cost-effective in some populations at increased risk of CKD, the cost-utility of renal screening in PPI users is unknown. AIM: To assess the cost-utility of regular interval creatinine screening vs. usual care to minimize costs associated with incidence of CKD and subsequent progression to end-stage renal disease (ESRD). METHODS: A Markov model was designed to evaluate the cost-utility, from a Medicare payer perspective, of routine screening versus usual care among a hypothetical population of ten million elderly (age $65) U.S. individuals with no baseline CKD who are using PPIs. Twelve-month transition probabilities between four health states (no disease, CKD, ESRD, and death) were derived from the literature. Outcomes included the number of deaths averted, total per-person costs associated with CKD and ESRD screening and treatment, and total per-person quality-adjusted life years (QALYs), over a time horizon of twenty years. Cost-utility was evaluated using incremental cost-utility ratios (ICURs) in terms of cost per QALY gained, assuming an annual discount rate of 3%. In deterministic sensitivity analysis, we evaluated the robustness of the primary results when doubling the probabilities of CKD incidence and progression to reflect a population with established risk factors such as diabetes or hypertension. We also performed a threshold analysis to assess scenarios S-455 AGA Abstracts under which screening would no longer be cost-effective. RESULTS: Over a 20-year time horizon, screening was associated with fewer deaths (screening vs. usual care; 5.09 vs. 5.26 million). At a willingness-to-pay (WTP) threshold of $50,000 per QALY gained, routine screening appeared to be cost-effective (ICUR $16,301 per QALY gained), with marginally higher total per-person costs ($206,099 vs. $204,021) and slightly higher per-person QALYs (11.5 vs. 11.4). The screening strategy was more cost-effective in populations with doubled risk of CKD incidence and progression (ICUR $7,433 per QALY gained), with patients in the screening strategy experiencing higher per-person costs ($215,268 vs. $213,496), fewer deaths at the population level (6.64 vs. 6.91 million), and more per-person QALYs (10.1 vs. 9.9). Screening was no longer cost-effective at the $50,000 WTP threshold in populations with very low incidence of CKD (<0.1% per year). CONCLUSIONS: Routine creatinine screening appears to be cost-effective in patients $65 years without CKD who are using a PPI, but costs and QALY gains are marginal. The cost-utility is improved in higher-risk populations with diabetes and/or hypertension, but screening may not be cost-effective in populations with very low incidence of CKD. Figure 1. Markov Model to Assess the Cost-Utility of Screening for Renal Dysfunction to Detect the Onset and Progression of Chronic Kidney Disease among Elderly Patients Treated with Proton-Pump Inhibitors. Su1016 COST-UTILITY ANALYSIS OF POTASSIUM-COMPETITIVE ACID BLOCKER- BASED THERAPEUTIC STRATEGY FOR GASTROESOPHAGEAL REFLUX DISEASE COMPARED WITH PROTON-PUMP INHIBITOR-BASED STRATEGY Kazuhide Higuchi, Akihito Uda, Hisato Deguchi, Kazuo Ueda, Yasuhito Watanabe, Kosuke Iwasaki, Ataru Igarashi Objective: Proton-pump inhibitors (PPIs) have been the first-line drugs for gastroesophageal reflux disease (GERD); however, potassium-competitive acid blockers (PCABs) were recently released as alternative drugs. To evaluate whether the PCAB-based therapeutic strategy is superior to the currently used PPI-based strategy, we conducted a cost-utility analysis of the PCAB-based strategy compared with PPI-based strategy. Methods: Based on the practice guideline for GERD, the following therapeutic strategy, consisting of healing and maintenance therapies was used for PPI and PCAB. Healing therapy starts with administering a normal dose of drug for 2 months, and if the patients are not healed, the dose is doubled for another 2 months. Successfully healed patients subsequently receive maintenance therapy, which commences with a normal drug dose for 6 months, followed by half of this dose for another 6 months. The half-dose maintenance therapy continues until the end of observation period, which was set to 3 years. Patients who had a relapse or were not healed after doubling the drug dose were started on the healing therapy from the beginning. For this strategy, esomeprazole (normal dose, 20 mg/day) and vonoprazan (normal dose, 20mg/day) were used as the PPI and PCAB, respectively. The Markov model was used to simulate these therapeutic strategies. Expected values of costs, quality-adjusted life year (QALY), and incre- mental cost-effectiveness ratio (ICER) were calculated by using the current cost of the drug, visit and physical examination, and endoscopic examination. For example, the cost of normal doses of PPI and PCAB was USD1.29 and USD 2.14, respectively. The cost was calculated from the perspective of healthcare payers in Japan. QOL scores for unhealed and healed patients was set to 0.72 and 0.56, respectively based on a previous report by Grand et al. (2008). Results: Annual expected costs for the PPI- and PCAB-based strategies were USD 479.57 and USD 675.10 yearly, respectively. The gain of QALY of the PCAB-based strategy was 0.01254 relative to that of the PPI-based strategy (Table 1). The ICER of the PCAB- based therapy was USD 15,593.17/QALY against PPI-based therapy. Conclusion: These results indicate that the PCAB-based strategy increased the QALY of patients compared to the PPI-based strategy. The ICER values were lower than proposed threshold value in Japan (JPY5-6Mil./QALY). Therefore, the PCAB-based strategy could be cost-effective. In practice, PCAB-based strategy has variations, and the strategy we used may be more conservative than other PCAB-based strategies. In future, a cost-utility analysis will also be performed for the other PCAB-based strategies. Table1. Cost and quality-adjusted life year (QALY) values of proton-pump inhibitor (PPI)- and potassium-competitive acid blocker (PCAB)-based therapies, their differential ( Δ) values, and incremental cost-effectiveness ratio (ICER) of PCAB-based therapy compared w AGA Abstracts